MX2021008645A - Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk). - Google Patents
Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk).Info
- Publication number
- MX2021008645A MX2021008645A MX2021008645A MX2021008645A MX2021008645A MX 2021008645 A MX2021008645 A MX 2021008645A MX 2021008645 A MX2021008645 A MX 2021008645A MX 2021008645 A MX2021008645 A MX 2021008645A MX 2021008645 A MX2021008645 A MX 2021008645A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- cdk inhibitor
- relates
- compositions
- methylcyclopentyl
- Prior art date
Links
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
- QIEKHLDZKRQLLN-FOIQADDNSA-N 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F QIEKHLDZKRQLLN-FOIQADDNSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se refiere a una forma cristalina de la base libre de 6-(difluorometil)-8- [(1R,2R)-2-hidroxi-2-metilciclopentil]-2-{ [1-(metilsulfonil)piperidin-4-il]amino}pirido[2,3-d]pirimidin-7(8 H)-ona (PF-06873600) (Forma 1); la invención también se refiere a composiciones farmacéuticas que comprenden esta forma cristalina, y a métodos de uso de la forma cristalina y dichas composiciones para el tratamiento de crecimiento celular anormal, tal como el cáncer, en un mamífero.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962793516P | 2019-01-17 | 2019-01-17 | |
| US201962949990P | 2019-12-18 | 2019-12-18 | |
| PCT/IB2020/050240 WO2020148635A1 (en) | 2019-01-17 | 2020-01-13 | Crystalline form of a cdk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008645A true MX2021008645A (es) | 2021-08-19 |
Family
ID=69326588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008645A MX2021008645A (es) | 2019-01-17 | 2020-01-13 | Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220127262A1 (es) |
| EP (1) | EP3911650A1 (es) |
| JP (2) | JP7036846B2 (es) |
| KR (1) | KR20210114996A (es) |
| CN (1) | CN113260617A (es) |
| AU (1) | AU2020209500B2 (es) |
| BR (1) | BR112021013050A2 (es) |
| CA (1) | CA3126788A1 (es) |
| MX (1) | MX2021008645A (es) |
| SG (1) | SG11202107225SA (es) |
| TW (1) | TWI745831B (es) |
| WO (1) | WO2020148635A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2619944C2 (ru) * | 2013-02-21 | 2017-05-22 | Пфайзер Инк. | Твердые формы селективного ингибитора CDK4/6 |
| MX382600B (es) * | 2015-07-31 | 2025-03-13 | Pfizer | Forma cristalina de base libre de lorlatinib. |
| LT3497103T (lt) | 2016-08-15 | 2021-07-26 | Pfizer Inc. | Piridopirimidinono cdk2/4/6 inhibitoriai |
-
2020
- 2020-01-13 KR KR1020217025743A patent/KR20210114996A/ko not_active Withdrawn
- 2020-01-13 CN CN202080009167.8A patent/CN113260617A/zh active Pending
- 2020-01-13 SG SG11202107225SA patent/SG11202107225SA/en unknown
- 2020-01-13 WO PCT/IB2020/050240 patent/WO2020148635A1/en unknown
- 2020-01-13 CA CA3126788A patent/CA3126788A1/en not_active Abandoned
- 2020-01-13 AU AU2020209500A patent/AU2020209500B2/en not_active Expired - Fee Related
- 2020-01-13 EP EP20702380.5A patent/EP3911650A1/en not_active Withdrawn
- 2020-01-13 MX MX2021008645A patent/MX2021008645A/es unknown
- 2020-01-13 US US17/423,143 patent/US20220127262A1/en not_active Abandoned
- 2020-01-13 BR BR112021013050-0A patent/BR112021013050A2/pt not_active Application Discontinuation
- 2020-01-14 TW TW109101197A patent/TWI745831B/zh not_active IP Right Cessation
- 2020-01-15 JP JP2020004195A patent/JP7036846B2/ja active Active
-
2021
- 2021-10-01 JP JP2021162502A patent/JP2021193151A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020209500B2 (en) | 2022-08-25 |
| KR20210114996A (ko) | 2021-09-24 |
| EP3911650A1 (en) | 2021-11-24 |
| JP7036846B2 (ja) | 2022-03-15 |
| TWI745831B (zh) | 2021-11-11 |
| CN113260617A (zh) | 2021-08-13 |
| JP2021193151A (ja) | 2021-12-23 |
| TW202043224A (zh) | 2020-12-01 |
| CA3126788A1 (en) | 2020-07-23 |
| SG11202107225SA (en) | 2021-08-30 |
| JP2020114808A (ja) | 2020-07-30 |
| AU2020209500A1 (en) | 2021-07-29 |
| US20220127262A1 (en) | 2022-04-28 |
| BR112021013050A2 (pt) | 2021-09-21 |
| WO2020148635A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008645A (es) | Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk). | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| AR120339A2 (es) | CRISTALES DE SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA | |
| PH12019500329A1 (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| ZA202001661B (en) | Crystalline form of lorlatinib free base hydrate | |
| PH12022550004A1 (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists | |
| CR20210251A (es) | Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| JO3754B1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
| TN2012000265A1 (en) | Triazolopyridines | |
| PH12013501758A1 (en) | Pyrazolo [1,5-a] pyridines as trk inhibitors | |
| MY142019A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| MX2012000166A (es) | Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos. | |
| MY150747A (en) | Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| MX336332B (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
| GB201302704D0 (en) | Therapeutic compounds |